Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Egile nagusia: | Paul, Pulock |
---|---|
Beste egile batzuk: | Azam,Faruque |
Formatua: | Thesis |
Hizkuntza: | English |
Argitaratua: |
Brac University
2024
|
Gaiak: | |
Sarrera elektronikoa: | http://hdl.handle.net/10361/23954 |
Antzeko izenburuak
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
nork: Rahman, Tasnim
Argitaratua: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
nork: Hoque, Ismoth Ara
Argitaratua: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
nork: Karim, Samia Binte
Argitaratua: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
nork: Flora, Sanzida Alam
Argitaratua: (2024) -
A review on targeted therapies for lung cancer
nork: Ashraf, Anushey
Argitaratua: (2023)